



## **Media Releases » Torrent Pharma records 25% growth in Revenues during Q2 13-14**

*October 30th, 2013*

Ahmedabad-based Pharmaceuticals major, Torrent Pharmaceuticals Limited, today released its financial results for the quarter ended 30th September, 2013. The Q2'13-14 revenues stood at Rs.972 crores, up by 25% from Rs.777 crores in the comparable quarter of last year.

During Q2, the domestic formulation business recorded revenues of Rs.297 crores, growing by 10%. During the quarter there were disruptions in the market on account of various demands of the trade, subsequent to the notification of DPCO 2013 and the related price notifications. This has impacted the overall market in the country with Torrent covered market as well as the overall Indian pharmaceutical market growing at only 3% as per AIOCD reports.

International revenues grew by 32% to Rs.573 crores. In the international operations, US business reported growth of 24%, Europe (incl. Heumann) 54%, Brazil growth 8% and Rest of the World, including Russia, CIS, Mexico & Canada 31%.

Profit before Taxes for the quarter was Rs.152 crores compared to Rs. 139 crores during the same period last year. Profit after Taxes for the quarter was Rs.113 crores compared to Rs.108 crores during the same period last year.

For H1, the revenues increased by 26% to Rs.1,944 crores compared with Rs.1,544 crores for the corresponding period last year. During H1, Profit before Taxes grew by 22% to Rs.339 compared to Rs.279 crores during the same period last year.

About Torrent Pharma: Torrent Pharma, with an annual turnover of over Rs.3200 crores is the flagship Company of the Torrent Group. With many of its products ranking among the top 200 brands, Torrent continues to be at the forefront of the Indian pharmaceutical industry. Torrent has a fully equipped Research Center, employing almost 600 scientists, to support the company's operations and product pipeline for both domestic and overseas markets. Torrent has manufacturing facilities located at Indrad, Baddi & Sikkim having facilities to produce Formulations and Bulk drugs. The plants are approved by authorities from various regulated and semi regulated markets like US, UK, Brazil, Germany, Australia and South Africa.

